Article Text

Download PDFPDF
An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover
  1. A P Cairns1,
  2. S A Wright1,
  3. A J Taggart1,
  4. S M Coward2,
  5. G D Wright1
  1. 1Department of Rheumatology, Musgrave Park Hospital, Belfast, Northern Ireland, UK
  2. 2Department of Biochemistry, Musgrave Park Hospital, Belfast, Northern Ireland, UK
  1. Correspondence to:
    Dr A Cairns
    Department of Rheumatology, Musgrave Park Hospital, Belfast BT9 7JB, UK; andrewcairnsdoctors.org.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Osteoporosis is a common feature of ankylosing spondylitis (AS), and vertebral fractures are an increasingly recognised complication. A cumulative fracture prevalence of between 9.5% and 18% has been reported, with a six- to eightfold relative increased risk of vertebral fracture.1–3 Osteoporosis and new bone formation (syndesmophytosis) suggest that disordered bone turnover has a role in disease pathogenesis in AS. Bisphosphonates accumulate at sites of increased bone turnover, and inhibit bone resorption by inducing osteoclast apoptosis,4 thereby improving bone density and reducing fracture rates.5 Pulse pamidronate has recently been used with clinical efficacy in the treatment of AS.6,7 Biochemical markers of bone turnover have been used to monitor response to treatment in postmenopausal osteoporosis.8

The effect of bisphosphonate treatment on biochemical bone turnover markers has not previously been studied in AS. We aimed at studying the efficacy of pulse pamidronate treatment in severe AS, and at determining its effect …

View Full Text